Sodium‑glucose cotransporter‑2 inhibitors in obesity and associated cardiometabolic disorders: where do we stand?
{{output}}
As the tide of obesity and its complications are on the rise, there is an urgent need for new drugs with weight‑lowering and beneficial metabolic properties. Obesity‑related disorders, such as metabolic syndrome, prediabetes, type 2 diabetes (T2D), cardiovas... ...
